Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new study from the Kennedy Institute of Rheumatology reveals a role for blood vessels in promoting therapy resistance of cancer metastasis in bone.

Confocal image showing subtypes of blood vessels (red, green and white) in bone. The new research links certain types of blood vessel cells to therapy resistance in tumour metastasis.

The research led by Dr Anjali Kusumbe’s team at the Kennedy Institute and published in JCI Insight shows that cells called pericytes that attach to blood vessels can halt the growth of cancer cells that have travelled from the primary tumour to bones. 

The researchers found increased numbers of pericytes in bones following chemotherapy or radiation, together with more of the proteins they secrete that keep cancer cells in check. As chemotherapy targets actively diving cells, these findings suggest pericytes might promote resistance to therapy.

Speaking of the research, Anjali said, “This is an offshoot of our research programme on understanding the vascular maladaptation during ageing, bone diseases and cancer. Blood vessels provide inductive signals during organ growth and form nurturing niches for multiple adult stem cells in the body. Our study shows that the vascular niches in bone respond differentially to cancer therapies and secrete factors to protect cancer cells during treatments”.        

Treatment with cancer therapies caused blood vessels in bone to secrete more of a molecule called PDGF2, which activates pericytes. Anjali explains “We identified blood flow and PDGF as a regulator of pericyte expansion in bone during treatment with cancer therapies. Use of blood flow modulators in combination with conventional cancer therapies render disseminated tumour cells in bones susceptible to these therapies, providing a possible strategy to target these cells to prevent bone metastasis”.     

Pericytes became less effective at subduing cancer cells with age, which may explain why cancer returns in the bones of some patients many years after treatment. 

The researchers are now focusing their attention on identifying therapeutic targets in the bone marrow microenvironment for managing age-related metastatic relapse. 

The work was supported by the European Research Council, Leuka, Medical Research Council, Royal Society, CRUK Development Fund and the Kennedy Trust for Rheumatology Research.

Similar stories

Behind enemy lines: research finds a new ally in the fight against cardiovascular disease hidden within the vessel wall itself

A new study reveals the existence of a powerful ally in the fight against cardiovascular disease, a protective subset of vascular macrophages expressing the C-type lectin receptor CLEC4A2, a molecule which fosters "good" macrophage behaviour within the vessel wall.

A drug being trialled to treat cancer, could be the key to reducing gut inflammation

Published in Nature Communications, a new study reveals a new signalling pathway behind macrophage inflammatory activity

Large genetic study suggests shared biological processes cause irritable bowel syndrome and anxiety

An international study of more than 50,000 people with irritable bowel syndrome (IBS) has revealed that IBS symptoms may be caused by the same biological processes as conditions such as anxiety. The research highlights the close relationship between brain and gut health and paves the way for development of new treatments.

New therapeutic targets identified to treat inflammatory bowel disease

Millions of patients with ulcerative colitis or Crohn’s disease, collectively known as inflammatory bowel disease (IBD), are given fresh hope as a new study shows why some of them do not respond to current treatments.

Labelling proteins through the diet gives new insights into how collagen-rich tissues change as we age

A new study, published in eLife, uses advanced tissue analysis technology to show how the incorporation of new proteins changes in bone and cartilage with age.

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.